Numerous clinical studies have established that angiotensin II receptor blockers are effective as antihypertensive therapy and are well tolerated. Studies demonstrate that adding an angiotensin II ...

[16] Postinfarction, ACE inhibitors and ß and blockers improve survival in patients ... The OPtimal Trial In Myocardial Infarction with the Angiotensin II Antagonist Losartan (OPTIMAAL ...

In terms of branded sales, the angiotensin II receptor blocker class dominates with five of the top ten antihypertensives belonging to this class and generating sales of $10.6 billion in 2006.

Prophylactic cardiac treatment may prolong survival in Duchenne muscular dystrophy (DMD), but only one-quarter of individuals ...

Seasonal influenza, respiratory syncytial virus (RSV), and COVID-19 are actively circulating throughout the United States.

A recent study from Columbia University has raised important questions about the medications used to treat high blood ...

Dimerix has achieved a key milestone in its ACTION3 phase III trial of lead asset DMX-200 into focal segmental ...

Acute coronary syndrome (ACS) is a term used to describe a range of conditions resulting from the sudden reduction or ...

ACTION3 is evaluating the efficacy and safety of DMX-200 in patients with FSGS who are receiving a stable dose of an angiotensin II receptor blocker (ARB). Once the ARB dose is stable, patients ...

On January 10, 2025, the US Court of Appeals for the Federal Circuit issued a precedential opinion in Novartis Pharmaceuticals Corp. v. Torrent ...

Heart Failure (HF) is a global pandemic accounting for 56 million prevalent cases worldwide (1). It is also a chronic progressive syndrome characterized by a progressive decline in quality of life and ...